peracetate pulicarine | 656236-73-6

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 黄酮类化合物
• 英文名称: peracetate pulicarine
• 英文别名: ST024734；5-(6-Acetyloxy-3,5,7-trimethoxy-4-oxochromen-2-yl)-2-methoxyphenyl acetate；[5-(6-acetyloxy-3,5,7-trimethoxy-4-oxochromen-2-yl)-2-methoxyphenyl] acetate
• CAS: 656236-73-6
• 化学式: C₂₃H₂₂O₁₀
• mdl: MFCD02184631
• 分子量: 458.422
• InChiKey: FWZKNPRCZCUJMQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  33
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  116
• 氢给体数：
  0
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  6-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-3,5,7-trimethoxychromen-4-one 、 乙酸酐 在 吡啶 作用下， 生成 peracetate pulicarine
  参考文献：
  名称：

  Flavonoid pulicarpin from Pulicaria salviifolia and its hypolipidemic activity

  摘要：

  DOI：

  10.1007/bf00630242

文献信息

• Horie Tokunaru, Tominaga Hideaki, Yoshida Isao, Kawamura Yasuhiko, Bull. Chem. Soc. Jap., 66 (1993) N 3, S 877-881
  作者：Horie Tokunaru, Tominaga Hideaki, Yoshida Isao, Kawamura Yasuhiko

  DOI：——

  日期：——
• SMALL MOLECULES FOR EXTENDING THE WELL BEING OF CELLS AND METHODS OF USE THEREOF
  申请人：Seng Eng Khuan

  公开号：US20150291547A1

  公开（公告）日：2015-10-15

  The present invention relates to use of a series of compounds and compositions comprising the same for enhancing telomerase expression and/or activating telomerase activity in a cell or tissue of a subject and for treatment of diseases, disorders and/or conditions capable of being affected by enhanced telomerase expression and/or telomerase activation.
• [EN] DRUGS FROM SUBSTITUTED PHENYL CINNAMYL KETONES<br/>[FR] MÉDICAMENTS OBTENUS À PARTIR DE PHÉNYL CINNAMYL CÉTONES SUBSTITUÉES
  申请人：NANYANG POLYTECHNIC

  公开号：WO2016153432A1

  公开（公告）日：2016-09-29

  The present invention relates to substituted phenyl cinnamyl ketones of Formula (I) for use in therapy: wherein R1 to R11 are defined as described in the specification, or a pharmaceutically acceptable salt, tautomer(s), solvate or polymorph thereof, that are used in the treatment on RNA virus related infections. The present invention also relates to use of the compounds as described in the specification for the manufacture of a medicament in the treatment of a disease associated with RNA virus infections. The present invention also relates a method of preventing or treating a disease associated with a RNA virus related infection comprising administering to a subject in need of treatment a compound as described in the specification, or a pharmaceutically acceptable salt thereof.